The DOI matches its Crossref record; 259 of the 259 references it cites were found in a registry or an index.
RNAi therapeutic and its innovative biotechnological evolution
Abstract
Recently, United States Food and Drug Administration (FDA) and European Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic, ONPATTRO™ (Patisiran), for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first RNAi therapeutic all over the world, as well as the first FDA-approved treatment for this indication. As a milestone event in RNAi pharmaceutical industry, it means, for the first time, people have broken through all development processes for RNAi drugs from research to clinic. With this achievement, RNAi approval may soar in the coming years. In this paper, we introduce the basic information of ONPATTRO and the properties of RNAi and nucleic acid therapeutics, update the clinical and preclinical development activities, review its complicated development history, summarize the key technologies of RNAi at early stage, and discuss the latest advances in delivery and modification technologies. It provides a comprehensive view and biotechnological insights of RNAi therapy for the broader audiences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–259 of 259
Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes.
Dejneka, N. S., Wan, S., Bond, O. S., Kornbrust, D. J., & Reich, S. J. (2008) · PubMed Central · Cited by 53
Alnylam terminates revusiran program, stock plunges
Garber, K. (2016) · Nature Biotechnology · doi:10.1038/nbt1216-1213 · Cited by 53
Nemunaitis, J. J., Barve, M. A., Orr, D. W., Kuhn, J. A., Magee, M., Lamont, J., Bedell, C., Wallraven, G., Pappen, B. O., Roth, A., et al. (2014) · Oncology · doi:10.1159/000360993 · Cited by 51
Targeted In Vivo Delivery of siRNA and an Endosome-Releasing Agent to Hepatocytes
Sebestyén, M. G., Wong, S. C., Trubetskoy, V. S., Lewis, D. L., & Wooddell, C. I. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1538-5_10 · Cited by 50
van der Waart, A. B., Fredrix, H., van der Voort, R., Schaap, N. P., Hobo, W. A., & Dolstra, H. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1668-6 · Cited by 50
Anti-miRs Competitively Inhibit microRNAs in Argonaute Complexes
Hogan, D. J., Vincent, T. M., Fish, S., Marcusson, E. G., Bhat, B., Chau, B. N., & Zisoulis, D. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100951 · Cited by 50
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
Rao, D. D., Jay, C. M., Wang, Z., Luo, X., Kumar, P., Eysenbach, H., Ghisoli, M. L., Senzer, N. N., & Nemunaitis, J. J. (2016) · Molecular Therapy · doi:10.1038/mt.2016.93 · Cited by 50
Scomparin, A., Polyak, D., Krivitsky, A., & Satchi‐Fainaro, R. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.04.008 · Cited by 49
A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).
Demeure, M. J., Armaghany, T., Ejadi, S., Ramanathan, R. K., Elfiky, A. A., Strosberg, J., Smith, D. C., Whitsett, T. G., Liang, W. S., Sekar, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.2547 · Cited by 49
Cheng, Q., Huang, Y., Zheng, H., Wei, T., Zheng, S., Huo, S., Wang, X., Du, Q., Zhang, X., Zhang, H., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.043 · Cited by 48
Self-citationTafamidis: A Review of Its Use in Familial Amyloid Polyneuropathy
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0260-2 · Cited by 47
Demirjian, S., Ailawadi, G., Polinsky, M. S., Bitran, D., Silberman, S., Shernan, S. K., Burnier, M., Hamilton, M., Squiers, E. C., Erlich, S. S., et al. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.03.016 · Cited by 46
Schultheis, B. S., Strumberg, D., Kuhlmann, J. B., Wolf, M., Link, K., Seufferlein, T. T. W., Kaufmann, J., Gebhardt, F., Bruyniks, N., & Pelzer, U. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.385 · Cited by 45
Phadke, A. P., Jay, C. M., Wang, Z., Chen, S., Liu, S., Haddock, C., Kumar, P., Pappen, B. O., Rao, D. D., Templeton, N. S., et al. (2011) · DNA and Cell Biology · doi:10.1089/dna.2011.1240 · Cited by 43
Liu, J., Yu, D., Aiba, Y., Pendergraff, H. M., Swayze, E. E., Lima, W. F., Hu, J., Prakash, T. P., & Corey, D. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt693 · Cited by 43
Kong, W.-H., Sung, D., Shim, Y., Bae, K. H., Dúbois, P., Park, T. G., Kim, J.-H., & Seo, S.-W. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.034 · Cited by 40
Protease-triggered siRNA delivery vehicles
Rozema, D. B., Blokhin, A. V., Wakefield, D. H., Benson, J. D., Carlson, J. C., Klein, J. J., Almeida, L., Nicholas, A. L., Hamilton, H., Chu, Q., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.012 · Cited by 40
Zhou, J., Li, H., Xia, X., Herrera, A., Pollock, N., Reebye, V., Sodergren, M. H., Dorman, S., Littman, B. H., Doogan, D. P., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.018 · Cited by 39
Phase I clinical trial of adoptive cellular immunotherapy with APN401 in patients with solid tumors
Triozzi, P. L., Kooshki, M., Alistar, A. T., Bitting, R. L., Neal, A., Lametschwandtner, G., & Loibner, H. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p175 · Cited by 38
Systemic Administration of siRNA via cRGD-containing Peptide
Huang, Y., Wang, X., Huang, W., Cheng, Q., Zheng, S., Guo, S., Cao, H., Liang, X., Du, Q., & Liang, Z. (2015) · Scientific Reports · doi:10.1038/srep12458 · Cited by 38
Self-citationWei, Z., Huang, Y., Zhao, D., Hu, Z., Li, Z., & Liang, Z. (2015) · Scientific Reports · doi:10.1038/srep07618 · Cited by 37
Self-citationAllele-Selective Inhibition of Mutant Atrophin-1 Expression by Duplex and Single-Stranded RNAs
Hu, J., Liu, J., Jayaprakash, K. N., Lackey, J. G., Kuchimanchi, S., Rajeev, K. G., Manoharan, M., Swayze, E. E., Lima, W. F., Prakash, T. P., et al. (2014) · Biochemistry · doi:10.1021/bi500610r · Cited by 36
HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma
Wong, S. C., Cheng, W., Hamilton, H., Nicholas, A. L., Wakefield, D. H., Almeida, A., Blokhin, A. V., Carlson, J. C., Neal, Z. C., Subbotin, V. M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0471 · Cited by 35
In Vitro -Packaged SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer
Kimchi‐Sarfaty, C., Ben-nun-Shaul, O., Rund, D. G., Oppenheim, A., & Gottesman, M. M. (2002) · Human Gene Therapy · doi:10.1089/10430340252769815 · Cited by 34
Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor
Hwang, J., Chang, C., Kim, J. H., Oh, C. T., Lee, H. N., Lee, C., Oh, D., Lee, C., Kim, B. J., Hong, S. W., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.06.626 · Cited by 31
Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs
Hu, J., Rigo, F., Prakash, T. P., & Corey, D. R. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0655 · Cited by 31
Planté‐Bordeneuve, V., Lin, H., Gollob, J., Agarwal, S., Betts, M. B., Fahrbach, K. R., Chitnis, M., & Polydefkis, M. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1554648 · Cited by 31
Lee, D. U., Huang, W., Rittenhouse, K. D., & Jessen, B. A. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2011.0116 · Cited by 29
Soule, B., Tirucherai, G., Kavita, U., Kundu, S., & Christian, R. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30442-2 · Cited by 28
Deep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision
Denise, H., Moschos, S. A., Sidders, B. S., Burden, F., Perkins, H., Carter, N., Stroud, T., Kennedy, M. A., Fancy, S., Lapthorn, C., et al. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.73 · Cited by 27
Molecular Properties, Functional Mechanisms, and Applications of Sliced siRNA
Sun, G., Yeh, S. Y., Yuan, C. W.-Y., Chiu, M. J.-Y., Yung, B. S., & Yen, Y. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.73 · Cited by 26
Hill, A., Valls, A. G., Griffin, M., Munir, T., Borodovsky, A., Kawahata, N. H., McLean, H., Shi, K., Partisano, A. M., Kim, J. B., et al. (2016) · Blood · doi:10.1182/blood.v128.22.3891.3891 · Cited by 26
Butler, A. A., Price, C. A., Graham, J. L., Stanhope, K. L., King, S. M., Hung, Y.-H., Sethupathy, P., Wong, S. C., Hamilton, J., Krauss, R. M., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089508 · Cited by 25
Mihaila, R., Chang, S. D., Wei, A. T., Hu, Z. Y., Ruhela, D., Shadel, T. R., Duenwald, S., Payson, E., Cunningham, J. J., Kuklin, N. A., et al. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.017 · Cited by 24
Continuous Vector-free Gene Transfer with a Novel Microfluidic Chip and Nanoneedle Array
Huang, D., Zhao, D., Li, J., Wu, Y., Du, L., Xia, X., Li, X., Deng, Y., Li, Z., & Huang, Y. (2018) · Current Drug Delivery · doi:10.2174/1567201815666181017095044 · Cited by 24
Self-citationPhase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer
Barve, M. A., Wang, Z., Kumar, P., Jay, C. M., Luo, X., Bedell, C., Mennel, R. G., Wallraven, G., Brunicardi, F. C., Senzer, N. N., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.14 · Cited by 22
Kornek, M., Kornek, M., Limmer, A., Raskopf, E., Becker, U., Klöckner, M., Sauerbruch, T., & Schmitz, V. (2008) · Molecular Medicine · doi:10.2119/2008-00003.kornek · Cited by 22
Systemic and tumor-targeted delivery of siRNA by cyclic NGR and isoDGR motif-containing peptides
Huang, Y., Cheng, Q., Jin, X., Ji, J.-L., Guo, S., Zheng, S., Wang, X., Cao, H., Gao, S., Liang, X., et al. (2016) · Biomaterials Science · doi:10.1039/c5bm00429b · Cited by 22
Self-citationActivating frataxin expression by single-stranded siRNAs targeting the GAA repeat expansion
Shen, X., Kilikevičius, A., O’Reilly, D., Prakash, T. P., Damha, M. J., Rigo, F., & Corey, D. R. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.033 · Cited by 21
Golan, T., Hubert, A., Shemi, A., Segal, A., Dancour, A., Khvalevsky, E. Z., Ben-David, E., Raskin, S., Goldes, Y., Inbar, Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.4037 · Cited by 20
Single-Stranded Silencing RNAs: Hit Rate and Chemical Modification
Pendergraff, H. M., Debacker, A. J., & Watts, J. K. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0557 · Cited by 17
Differences in silencing of mismatched targets by sliced versus diced siRNAs
Sun, G., Wang, J., Huang, Y., Yuan, C. W.-Y., Zhang, K., Hu, S., Chen, L., Lin, R.-J., Yen, Y., & Riggs, A. D. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky287 · Cited by 17
Self-citationDelville, M., Touzot, F., Couzin, C., Hmitou, I., Djerroudi, L., Ouedrani, A., Lefrère, F., Tuchmann‐Durand, C., Mollet, C., Fabreguettes, J., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.02.006 · Cited by 17
Ghisoli, M. L., Rutledge, M., Stephens, P. J., Mennel, R. G., Barve, M. A., Manley, M., Oliai, B. R., Murphy, K. M., Manning, L., Gutierrez, B., et al. (2017) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000822 · Cited by 16
Wooddell, C. I., Zhu, R., Hamilton, H. L., Chu, Q., Sternard, H., Schumacher, J., Schluep, T., Seefeld, M. A., Li, Z., & Given, B. D. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30255-1 · Cited by 16
Hepatitis B Gene Therapy Coming to Age.
Soriano, V. (2018) · PubMed · Cited by 16
Loibner, H., Lametschwandtner, G., Westritschnig, K., Mutschlechner, O., Dohnal, A. M., Salzberg, M. O., & Triozzi, P. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3055 · Cited by 14
Trieu, V. N., Hwang, L., Ng, K., D’Cruz, O. J., Qazi, S., & Fong, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx393.041 · Cited by 12
Altamura, S., Altamura, S., Muckenthaler, M. U., Dames, S., Frauendorf, C., Schubert, S., Aleku, M., Vadolas, J., Grigoriadis, G., & Zügel, U. (2018) · Blood · doi:10.1182/blood-2018-99-110163 · Cited by 12
Sehgal, A., Blomenkamp, K., Qian, K., Simon, A. R., Haslett, P. A. J., Barros, S. A., & Teckman, J. H. (2015) · Gastroenterology · doi:10.1016/s0016-5085(15)33331-x · Cited by 11
Sun, G., & Riggs, A. D. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.07.008 · Cited by 11
Hayden, E. C. (2014) · Nature · doi:10.1038/508443a · Cited by 10
Patel, K., Kilfoil, G., Wyles, D. L., Naggie, S., Lawitz, E., Bradley, S., Lindell, P., & Suhy, D. A. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)33067-2 · Cited by 9
Gane, E. J., Schwabe, C., Given, B. D., Schluep, T., Hamilton, J., Lai, C., Locarnini, S., Lau, J. Y. N., Ferrari, C. I., & Gish, R. G. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30843-7 · Cited by 9
RNA Interference-Mediated Gene Silencing by Branched Tripodal RNAs Does Not Require Dicer Processing
Kim, Y., Kang, Y. G., Choe, J. Y., Lee, D., Shin, C., Hong, S. W., & Lee, D.-K. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0681 · Cited by 9
Overcoming the Challenges of RNAi-based therapy: an Interview With James Hamilton
Hamilton, J. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0030 · Cited by 9
Melquist, S., Wakefield, D. H., Hamilton, H., Chapman, C., Grondolsky, J., Schienebeck, C. M., Almeida, L., Klas, C., Hagen, C. M., Almeida, A., et al. (2016) · Circulation · Cited by 7
Wooddell, C. I., Blomenkamp, K., Chen, H., Griffin, J., Zhu, R., Chu, Q., Hamilton, H. L., Hegge, J., Christianson, D. R., Li, Z. H., et al. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30383-0 · Cited by 6
Alnylam interrupts preeclampsia
Haas, M. J. (2014) · Science-Business eXchange · doi:10.1038/scibx.2014.1170 · Cited by 3
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Self-citationAdvances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 516
Self-citationThe growth of siRNA-based therapeutics: updated clinical studies
Zhang, M. M., Bahal, R., Rasmussen, T. P., Manautou, J. E., & Zhong, X.-B. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114432 · Cited by 497
Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects
Zu, H., & Gao, D. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00608-7 · Cited by 475
A Hitchhiker’s Guide to Click-Chemistry with Nucleic Acids
Fantoni, N. Z., El-Sagheer, A. H., & Brown, T. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00928 · Cited by 462
Metadata
- Authors
- Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 37
- Issue
- 5
- Pages
- 801-825
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W2942046145
- Cited by
- 286
- References
- 259
- FWCI
- 11.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.